vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and MITEK SYSTEMS INC (MITK). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $44.2M, roughly 1.7× MITEK SYSTEMS INC). MITEK SYSTEMS INC runs the higher net margin — 6.3% vs -121.9%, a 128.2% gap on every dollar of revenue. On growth, MITEK SYSTEMS INC posted the faster year-over-year revenue change (18.8% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $6.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -2.9%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Mitek Systems, Inc. is a software company that specializes in digital identity verification and mobile image processing using artificial intelligence. The company's software is used for depositing checks and opening bank accounts via mobile devices. It also verifies identity documents such as passports, ID cards, and driver's licenses by analyzing a selfie of an individual holding their ID, comparing their face to the photo on the document.

HCAT vs MITK — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.7× larger
HCAT
$74.7M
$44.2M
MITK
Growing faster (revenue YoY)
MITK
MITK
+25.0% gap
MITK
18.8%
-6.2%
HCAT
Higher net margin
MITK
MITK
128.2% more per $
MITK
6.3%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$3.0M more FCF
HCAT
$9.6M
$6.6M
MITK
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-2.9%
MITK

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HCAT
HCAT
MITK
MITK
Revenue
$74.7M
$44.2M
Net Profit
$-91.0M
$2.8M
Gross Margin
Operating Margin
-115.3%
12.3%
Net Margin
-121.9%
6.3%
Revenue YoY
-6.2%
18.8%
Net Profit YoY
-340.3%
160.1%
EPS (diluted)
$-1.29
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
MITK
MITK
Q4 25
$74.7M
$44.2M
Q3 25
$76.3M
$44.8M
Q2 25
$80.7M
$45.7M
Q1 25
$79.4M
$51.9M
Q4 24
$79.6M
$37.3M
Q3 24
$76.4M
$43.2M
Q2 24
$75.9M
$45.0M
Q1 24
$74.7M
$47.0M
Net Profit
HCAT
HCAT
MITK
MITK
Q4 25
$-91.0M
$2.8M
Q3 25
$-22.2M
$1.9M
Q2 25
$-41.0M
$2.4M
Q1 25
$-23.7M
$9.2M
Q4 24
$-20.7M
$-4.6M
Q3 24
$-14.7M
$8.6M
Q2 24
$-13.5M
$216.0K
Q1 24
$-20.6M
$282.0K
Gross Margin
HCAT
HCAT
MITK
MITK
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
MITK
MITK
Q4 25
-115.3%
12.3%
Q3 25
-22.9%
10.5%
Q2 25
-46.0%
8.3%
Q1 25
-25.4%
21.9%
Q4 24
-22.0%
-8.3%
Q3 24
-17.9%
17.8%
Q2 24
-20.8%
1.6%
Q1 24
-30.5%
1.5%
Net Margin
HCAT
HCAT
MITK
MITK
Q4 25
-121.9%
6.3%
Q3 25
-29.1%
4.2%
Q2 25
-50.8%
5.2%
Q1 25
-29.9%
17.6%
Q4 24
-26.0%
-12.4%
Q3 24
-19.3%
19.8%
Q2 24
-17.8%
0.5%
Q1 24
-27.6%
0.6%
EPS (diluted)
HCAT
HCAT
MITK
MITK
Q4 25
$-1.29
$0.06
Q3 25
$-0.32
$0.04
Q2 25
$-0.59
$0.05
Q1 25
$-0.35
$0.20
Q4 24
$-0.33
$-0.10
Q3 24
$-0.24
$0.19
Q2 24
$-0.23
$0.00
Q1 24
$-0.35
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
MITK
MITK
Cash + ST InvestmentsLiquidity on hand
$95.7M
$190.1M
Total DebtLower is stronger
$153.3M
$4.8M
Stockholders' EquityBook value
$245.8M
$233.7M
Total Assets
$502.6M
$446.5M
Debt / EquityLower = less leverage
0.62×
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
MITK
MITK
Q4 25
$95.7M
$190.1M
Q3 25
$91.5M
$193.0M
Q2 25
$97.3M
$167.1M
Q1 25
$342.0M
$136.2M
Q4 24
$392.0M
$121.2M
Q3 24
$387.3M
$130.3M
Q2 24
$308.3M
$123.1M
Q1 24
$327.8M
$123.9M
Total Debt
HCAT
HCAT
MITK
MITK
Q4 25
$153.3M
$4.8M
Q3 25
$153.1M
$4.3M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
$2.7M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
MITK
MITK
Q4 25
$245.8M
$233.7M
Q3 25
$331.9M
$240.3M
Q2 25
$347.5M
$237.6M
Q1 25
$376.8M
$220.2M
Q4 24
$365.2M
$200.9M
Q3 24
$355.0M
$214.8M
Q2 24
$357.0M
$209.6M
Q1 24
$357.2M
$216.1M
Total Assets
HCAT
HCAT
MITK
MITK
Q4 25
$502.6M
$446.5M
Q3 25
$587.1M
$459.1M
Q2 25
$616.2M
$446.7M
Q1 25
$891.5M
$425.3M
Q4 24
$858.9M
$396.0M
Q3 24
$813.0M
$413.8M
Q2 24
$691.7M
$409.2M
Q1 24
$695.1M
$417.0M
Debt / Equity
HCAT
HCAT
MITK
MITK
Q4 25
0.62×
0.02×
Q3 25
0.46×
0.02×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
0.01×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
MITK
MITK
Operating Cash FlowLast quarter
$9.9M
$8.0M
Free Cash FlowOCF − Capex
$9.6M
$6.6M
FCF MarginFCF / Revenue
12.9%
14.9%
Capex IntensityCapex / Revenue
0.4%
3.2%
Cash ConversionOCF / Net Profit
2.89×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$60.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
MITK
MITK
Q4 25
$9.9M
$8.0M
Q3 25
$-464.0K
$19.5M
Q2 25
$-9.0M
$21.6M
Q1 25
$280.0K
$13.7M
Q4 24
$-3.5M
$565.0K
Q3 24
$6.2M
$21.1M
Q2 24
$1.6M
$13.0M
Q1 24
$10.3M
$7.1M
Free Cash Flow
HCAT
HCAT
MITK
MITK
Q4 25
$9.6M
$6.6M
Q3 25
$-719.0K
$19.2M
Q2 25
$-9.2M
$21.2M
Q1 25
$-390.0K
$13.5M
Q4 24
$-3.9M
$230.0K
Q3 24
$5.5M
$20.8M
Q2 24
$1.3M
$12.6M
Q1 24
$10.1M
$6.6M
FCF Margin
HCAT
HCAT
MITK
MITK
Q4 25
12.9%
14.9%
Q3 25
-0.9%
42.9%
Q2 25
-11.4%
46.5%
Q1 25
-0.5%
26.0%
Q4 24
-4.9%
0.6%
Q3 24
7.2%
48.2%
Q2 24
1.7%
27.9%
Q1 24
13.5%
14.0%
Capex Intensity
HCAT
HCAT
MITK
MITK
Q4 25
0.4%
3.2%
Q3 25
0.3%
0.6%
Q2 25
0.3%
0.7%
Q1 25
0.8%
0.4%
Q4 24
0.5%
0.9%
Q3 24
0.9%
0.7%
Q2 24
0.4%
1.0%
Q1 24
0.3%
1.0%
Cash Conversion
HCAT
HCAT
MITK
MITK
Q4 25
2.89×
Q3 25
10.46×
Q2 25
9.00×
Q1 25
1.50×
Q4 24
Q3 24
2.46×
Q2 24
60.12×
Q1 24
25.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

MITK
MITK

Fraud And Identity Solutions$25.5M58%
License$13.9M31%
Fraud And Identity Solutions Software License And Support$3.9M9%
Professional Services And Other$1.2M3%

Related Comparisons